Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.
Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y; IMPROVE Study Group Expert Panel. Valensi P, et al. Among authors: shah s. Int J Clin Pract. 2008 Nov;62(11):1809-19. doi: 10.1111/j.1742-1241.2008.01917.x. Epub 2008 Sep 22. Int J Clin Pract. 2008. PMID: 18811598 Clinical Trial.
Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J; IMPROVE Study Expert Panel. Valensi P, et al. Among authors: shah s. Curr Med Res Opin. 2013 Jun;29(6):601-9. doi: 10.1185/03007995.2013.786692. Epub 2013 Apr 12. Curr Med Res Opin. 2013. PMID: 23488447
Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y; IMPROVE Study Group Expert Panel. Valensi P, et al. Among authors: shah s. Int J Clin Pract. 2009 Mar;63(3):522-31. doi: 10.1111/j.1742-1241.2009.02002.x. Epub 2009 Jan 27. Int J Clin Pract. 2009. PMID: 19187170 Clinical Trial.
Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
Shah S, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shestakova M, Wenying Y, Valensi P; IMPROVE Study Group Expert Panel. Shah S, et al. Int J Clin Pract. 2009 Apr;63(4):574-82. doi: 10.1111/j.1742-1241.2009.02012.x. Epub 2009 Feb 5. Int J Clin Pract. 2009. PMID: 19210701 Free PMC article. Clinical Trial.
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, Ligthelm R, Valensi P; IMPROVE Study Group Expert Panel. Gumprecht J, et al. Among authors: shah s. Int J Clin Pract. 2009 Jun;63(6):966-72. doi: 10.1111/j.1742-1241.2009.02064.x. Int J Clin Pract. 2009. PMID: 19504715 Free PMC article. Clinical Trial.
Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P; IMPROVE Study Group Expert Panel. Wenying Y, et al. Among authors: shah s. Curr Med Res Opin. 2009 Nov;25(11):2643-54. doi: 10.1185/03007990903276745. Curr Med Res Opin. 2009. PMID: 19751116
Predictors of postprandial blood glucose response to biphasic insulin analogue therapy.
Borzì V, Benroubi M, Gumprecht J, Kawamori R, Ligthelm R, Shaban J, Shah S, Shestakova M, Wenying Y, Valensi P; IMPROVE™ Study Expert Panel. Borzì V, et al. Among authors: shah s. Prim Care Diabetes. 2013 Apr;7(1):63-7. doi: 10.1016/j.pcd.2012.09.002. Epub 2012 Nov 20. Prim Care Diabetes. 2013. PMID: 23182405
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group. Marre M, et al. Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x. Diabet Med. 2009. PMID: 19317822 Free PMC article. Clinical Trial.
15,405 results
You have reached the last available page of results. Please see the User Guide for more information.